{
    "clinical_study": {
        "@rank": "166491", 
        "arm_group": [
            {
                "arm_group_label": "Human Serum Albumin/interferon alpha2a", 
                "arm_group_type": "Experimental", 
                "description": "Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C."
            }, 
            {
                "arm_group_label": "Pegasys", 
                "arm_group_type": "Active Comparator", 
                "description": "Peginterferon 180 mcg single dose S.C."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of\n      Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein single dose in Chinese\n      healthy volunteers."
        }, 
        "brief_title": "Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "This is an open-label study that will be conducted at a single site in China to characterize\n      the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon\n      alpha2a Fusion Protein in healthy subjects. Subjects will receive a single dose of\n      Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein or active comparator\n      Pegasys at Day 0. The total duration of study participation is up to 6 weeks for each\n      subject. Subjects will complete a follow-up visit at Day 28 after the dosing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be healthy males or females between 18 to 45 years old, inclusive\n\n          -  Must have a body mass index (BMI) of 19 to 25 kg/m2, inclusive, and a minimum body\n             weight of 50.0 kg\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant laboratory abnormalities, cardiac,\n             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,\n             neurologic, dermatologic, psychiatric, renal, or other major diseases\n\n          -  Female subjects who are pregnant or breastfeeding\n\n          -  Any previous treatment with Human Albumin Interferon fusion protein\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901198", 
            "org_study_id": "921301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Human Serum Albumin/interferon alpha2a", 
                "description": "Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0", 
                "intervention_name": "Human  Serum Albumin/interferon alpha2a  300-1200 mcg single dose S.C.", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Pegasys", 
                "description": "Pegasys 180 mcg S.C. single dose on Day 0", 
                "intervention_name": "Peginterferon 180 mcg single dose S.C.", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100069"
                }, 
                "name": "Beijing YouAn Hospital, Capital Medical University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Beijing YouAn Hospital", 
            "last_name": "Ning Li, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events after single dose", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901198"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentration of interferon after single dose", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Plasma concentration of Neopterin after single dose", 
                "safety_issue": "No", 
                "time_frame": "4 weks"
            }
        ], 
        "source": "Beijing Bio-Fortune Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Bio-Fortune Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}